Citigroup
ALGS icon

Citigroup’s Aligos Therapeutics ALGS Stock Holding History

Citigroup’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$9 – 5919
2025
Q4 		$9 Buy
+1
New +$9 ﹤0.01% 5814
2023
Q1 		– Sell
-3
Closed -$81 – 5463
2022
Q4 		$81 Sell
3
-20
-87% -$504 ﹤0.01% 5646
2022
Q3 		$1K Sell
23
-41
-64% -$1.36K ﹤0.01% 5601
2022
Q2 		$2K Sell
64
-214
-77% -$7.27K ﹤0.01% 5849
2022
Q1 		$15K Sell
278
-23
-8% -$1.84K ﹤0.01% 5301
2021
Q4 		$89K Buy
301
+176
+141% +$64.2K ﹤0.01% 4786
2021
Q3 		$48K Buy
125
+42
+51% +$16.6K ﹤0.01% 4750
2021
Q2 		$43K Buy
83
+35
+73% +$22.3K ﹤0.01% 4895
2021
Q1 		$27K Sell
48
-28
-37% -$18.6K ﹤0.01% 5068
2020
Q4 		$52K Buy
+76
New +$37K ﹤0.01% 6009

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citigroup's ALGS Position: Q1 2026 in Review

Citigroup sold out of Aligos Therapeutics (ALGS) in Q1 2026, closing a stake of 1 share — an estimated $9 sold.

Citigroup first reported a position in ALGS in Q4 2020 and held it in 10 quarters. The position peaked at $89K in Q4 2021. 35 funds tracked by Wall St. Rank hold ALGS as of Q1 2026.

  • Citigroup reported no remaining Aligos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Aligos Therapeutics share in Q1 2026, an estimated $9.
  • Citigroup first reported a position in Aligos Therapeutics in Q4 2020 and held it in 10 quarters.
  • Citigroup's Aligos Therapeutics position peaked at $89K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.